Sample size estimates for drug-drug interaction (DDI) studies are often based on variability information from the literature or from historical studies, but small sample sizes in these sources may limit the precision of the estimates obtained. This project aimed to create an intra-subject variability library of the pharmacokinetic (PK) exposure parameters, area under the curve, and maximum plasma concentration, for probes commonly used in DDI studies. Data from 66 individual DDI studies in healthy subjects relating to 18 common probe substrates were pooled to increase the effective sample size for the identified probes by 1.5-to 9-fold, with corresponding improvements in precision of the intra-subject PK variability estimates in this library. These improved variability estimates will allow better assessment of the sample sizes needed for DDI studies in future.
Introduction
Interactions between pharmacological agents can have clinically significant effects on the safety and efficacy profiles of individual treatment(s) by altering toxicity or reducing therapeutic effect [1] . United States Food and Drug Administration (FDA) guidance directs that the nature and magnitude of any potential drug-drug interactions (DDIs) are assessed as part of the characterization of the risk -benefit profile of new treatments [1] . The aims of such interaction studies are to determine if exposure to the new drug is affected by concomitant medication or, alternatively, if the new drug affects exposure to a concomitant medication; and to predict whether any such interaction would be clinically meaningful. The results of DDI studies can indicate whether precautionary measures such as dosage adjustments, therapeutic monitoring, or a contraindication to concomitant medication use, should be considered to mitigate risk. Therefore, it is important not only to ensure that DDI studies enroll sufficient subjects to establish the presence or absence of any interactions but also to minimize the number of subjects exposed to the investigational treatment, primarily to limit any undue safety risk but also to minimize costs.
Common DDI mechanisms include interactions that affect the normal metabolic elimination or activation of the drug, and interactions via transporters that impact absorption and clearance. For example, metabolic enzymes of the cytochrome P450 family are predominantly concentrated in the liver and intestines [2] and provide a major route of drug clearance. Inhibition or induction of individual cytochrome P450 enzymes can have a clinically significant impact on a subject's exposure to a given drug [3] . In addition, transporters such as P-glycoprotein and organic anion-transporting polypeptides play a key role in the absorption and elimination of drugs, both overall [4, 5] and by individual organs [6, 7] . Importantly, the potential for any such interaction must be assessed even if a particular enzyme or transporter is not involved in the elimination of the investigational drug, as the drug may induce or inhibit the activity of the enzyme/transporter and so affect the metabolism or elimination of a co-administered treatment.
DDI studies are commonly designed as crossover studies, either with (multiple sequences) or without (single sequence) randomization. Evaluation of the DDI potential of new drugs depends on reliable probe substrates [1] . An ideal probe substrate is one that has a well-defined pharmacokinetic (PK) profile, including its absorption, distribution, metabolism, and elimination; a known inhibitory or inducing effect on a specific enzyme or transporter; and a good safety profile, as determined from extensive clinical study. Consequently, the majority of DDI studies draw from a small pool of well-characterized and widely used probes [8] .
As required by the FDA, the results of DDI studies are reported as 90% CIs about the geometric mean ratio (GMR) of each PK parameter, with or without the interacting drug [1] . Sample size calculations for these studies are usually based on the variability information available in the literature, assuming a log-normal distribution for the area under the concentration -time curve (AUC) and the maximum plasma concentration (C max ) with appropriate intra-subject variability estimates available. As most DDI studies have a crossover design, intra-subject variability is more relevant than between-subject variations to sample size determination. Unfortunately, intrasubject variability estimates are often derived from a single historical DDI study, usually with a small sample size. This creates the potential for large sampling errors and inaccurate estimates of intra-subject variability that can result in imprecise estimates of DDI effects. Therefore, it is important to maximize the precision of the intra-subject variability estimate by increasing the sample size. However, it should be noted that although variance (as shown by the standard error of the estimated SD) clearly decreases as sample size increases ( Fig. 1) , the gain in precision becomes limited with sample sizes of more than 60-80 individuals, and then marginalized with sample sizes of more than 100. This suggests a manageable framework within which accurate estimates of intra-subject PK variability can be obtained.
By pooling data from a set of well-controlled DDI studies to generate larger effective sample sizes, more precise intra-subject variability estimates can be obtained compared with those from the individual studies alone. The aim of this project was to pool data for commonly used probe substrates from multiple clinical pharmacology studies conducted by Bristol-Myers Squibb Company (BMS) and thus provide a library of variability estimates to inform and improve sample size calculations in future DDI studies.
Methods

Identification of Studies and Substrates for Inclusion in the Library
Variability information for drug exposure PK parameters of common probe substrates was investigated using available data from all historical BMS-sponsored DDI studies that investigated the effects on probe PK in healthy subjects and were conducted between 2006 and 2014. The protocols for all studies identified were broadly similar, with similar inclusion and exclusion criteria. In all studies, subjects were required to abstain from using prescription and over-the-counter medications, with the exception of those prescribed by the investigator for the treatment of an adverse event. Where concomitant medication was prescribed, the subject was excluded from the analysis if it was considered possible that the medication could have affected the outcome of the study (i.e., the PK parameter under investigation). The majority of studies were performed under fasted conditions, although in some studies dosing could also be done with a light meal if the food effect was not considered relevant. Studies were reviewed to identify those using a probe substrate adopted in 2 or more cases ("common" probe substrates), which were then included in the variability library.
Statistical Analysis
The 90% CIs of the GMR of the AUC and C max for each probe substrate were obtained from each individual study in the library. All statistical analyses were performed using Excel (Microsoft, Redmond, WA, USA). Intra-subject SDs for individual studies were calculated using the formula:
ln upper bound of % CI ln GMR tailed inverse of student t distribution degrees of freedom n
Pooled multiple studies for each probe substrate were used to obtain an improved estimate of the intra-subject SD of the AUC and C max on the log scale based on the increased effective sample size using the following equation:
Individual studies effective degrees of freedom intra subject SD
Total effective degrees of freedom
Results
A total of 18 common probe substrates were identified (Table 1) and 66 individual DDI studies relating to these probes were included in the library. A summary of the intra-subject SDs in the individual studies included in the analysis is available in online Supplementary Table 1 (for all online suppl. material, see www.karger.com/ doi/10.1159/000485516; single-dose studies) and online supplementary Table 2 (multiple-dose studies). Data from 2 to 10 individual studies per probe, providing a sample size of up to 196 subjects per probe, were pooled and intra-subject SDs for AUC inf , AUC 0-t , and C max for single-dose studies (Table 2) and AUC tau and C max for multiple-dose studies (Table 3) were generated from the pooled data.
Discussion
In this study, we achieved our goal of providing more precise variability estimates for common DDI probe substrates by pooling a large amount of data from historical BMS-sponsored DDI studies (n = 66) to enhance sample sizes compared with individual studies. Improved intrasubject variability estimates were obtained for 18 common probe substrates in our library, including all of the phase 1 metabolizing enzymes that the FDA recommends assessing for possible DDIs [1] .
FDA guidance advises that the appropriate sample size for a DDI study depends on the size of the effect that it is clinically important to detect or rule out [1] . Multiple factors, including the intra-subject variability estimate and the sample size, can significantly affect the likelihood of detecting such effects. By pooling subject numbers across multiple studies, information from the current library provides an effective sample size that is 1.5-to 9-fold larger than that of the individual DDI studies. Such an increased sample size for intra-subject variability estimates reduces the SE of the SD, with a corresponding increase in the precision of variability estimates (Fig. 1) and rapidly diminishing additional benefit beyond a sample size of more than 60-80 individuals.
The impact of such improved estimates on sample size calculations is best illustrated by an example. In the 5 rosuvastatin studies included in this analysis (Table 2 ; online suppl. Table 1 ), estimates of intra-subject SD for C max a Intra-subject SD was calculated from pooled intra-subject SD estimates using 90% CI and geometric mean ratio data from each individual study. For full details of how this was calculated, please see the Statistical Analysis section of the text.
b n = the number of subjects included in the calculation where this deviates from the total number of subjects. AUC tau , area under the concentration -time curve across one complete dosing interval; C max , maximum plasma concentration; QD, once daily. [4] ) 0.111 (n = 94 [4] ) Dextromethorphan 30 3 16-20 52 0.293 0.339 (n = 36 [2] ) 0.349 (n = 36 [2] [7] ) 0.186 (n = 148 [7] ) 2 or 5 (oral) 10 14-36 196 0.162 0.167 (n = 176 [9] ) 0.205 (n = 176 [9] ) a Intra-subject SD was calculated from pooled intra-subject SD estimates using 90% CI and geometric mean ratio data from each individual study. For full details of how this was calculated, please see the Statistical Analysis section of the text.
b n = the number of subjects included in the calculation where this deviates from the total number of subjects; superscript values in square brackets indicate the number of studies included in the calculation where this differs from the total number of studies.
Superscript values in square brackets indicate the number of studies included in the calculation where this differs from the total number of studies.
AUC 0-t , area under the concentration -time curve from time 0 to the last measured plasma concentration; AUC inf , area under the concentration -time curve from time 0 to infinity; C max , maximum plasma concentration.
DOI: 10.1159/000485516 varied significantly in the individual studies, ranging from 0.19 to 0.51, indicating large sampling errors. This can be compared with the pooled intra-subject SD of 0.332.
Although DDI studies are not usually designed to test a formal hypothesis with a given power, some level of precision for the GMR estimate is expected. If designing a study so as to limit the width of the 90% CI to <30% (when GMR = 1), the number of subjects required would vary from 9 to 64 based on the lower and upper bound estimates of intra-subject variability from the individual studies. This compares with 40 subjects as estimated using our pooled variability data. Similarly, if the study were to restrict the width of the 90% CI to <50%, it would need 4-24 individuals based on the individual study 90% CI lower and upper bounds, or 15 individuals based on the pooled estimate.
We acknowledge that a drug's metabolism can be influenced by other factors, including genetic polymorphisms in key transporters or metabolic enzymes among individuals [9] [10] [11] [12] [13] [14] , and FDA guidance on DDI studies recommends that genotype information for enzymes or transporters should be included for each subject where relevant [1] . One potential limitation of the current analysis is that the library does not incorporate information on racial or genetic heterogeneity within or across the included studies. However, most of the included studies were US-based, and were conducted in healthy volunteers with few restrictions on enrolment. Therefore, this lack of information would not be expected to significantly affect the interpretation of the results.
In summary, by pooling population data from multiple DDI studies, the variability library presented here provides more precise intra-subject variability estimates for 18 commonly used DDI probe substrates than can be obtained from the individual studies alone. This information should facilitate improvements in sample size calculations for future DDI studies. Greater precision in variability estimates is key for determining the number of subjects required to establish the presence or absence of DDIs, while minimizing the number of subjects exposed to the investigational treatment.
